Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience
The Breast Journal Jan 10, 2018
Martin-Romano P, et al. - The efficacy, toxicity, and long-term outcome of the combination of pegylated liposomal doxorubicin (PLD) plus gemcitabine (GEM) in heavily pretreated metastatic breast cancer (MBC) patients were assessed. The PLD-GEM combination resulted in remarkable long-term outcomes with an acceptable toxicity profile in these patients.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
